

HETEROCYCLES, Vol. 91, No. 10, 2015, pp. 1926 - 1936. © 2015 The Japan Institute of Heterocyclic Chemistry  
Received, 9th August, 2015, Accepted, 14th September, 2015, Published online, 24th September, 2015  
DOI: 10.3987/COM-15-13300

## FOUR NEW COMPOUNDS FROM *POUZOLZIA ZEYLANICA* (L.) BENN.

### VAR. *MICROPHYLLA*


**Chu-Qian Zhong, Shu-Hong Tao, Zhi-Bo Yi, Li-Bing Guo,\* Yu-Feng Xie,  
and Yan-Fen Chen**

School of Traditional Chinese Medicine, Guangdong Pharmaceutical University,  
University City, 280 Waihuan East Road, Guangzhou, Guangdong, 510006, P. R.  
China; E-mail: guolibing512@126.com

**Abstract** – Two new stilbenes, pouzolignan D (**1**) and K (**2**), and two new norlignans, pouzolignan L (**3**) and M (**4**), together with four known flavonoids, rhamnocitrin (**5**), rhamnetin (**6**), isorhamnetin (**7**) and quercetin (**8**), were isolated from the aerial parts of *Pouzolzia zeylanica* (L.) Benn. var. *microphylla* (Wedd.) W. T. Wang. Their structures were elucidated by spectroscopic methods, including UV, IR, HR-ESI-TOF-MS, 1D and 2D NMR experiments.

## INTRODUCTION

*Pouzolzia zeylanica* (L.) Benn. var. *microphylla* (Wedd.) W. T. Wang (Urticaceae), one of the four medicinal plants in the genus *Pouzolzia*, is extensively distributed in Japan, India, Malaysia, Indonesia, Australia and South China.<sup>1,2</sup> It has been traditionally used for the treatment of gangrenous ulcers, sores, boils, diarrhea, syphilis, gonorrhoea, etc.<sup>3-5</sup> A series of compounds including flavonoids, lignans, norlignans and triterpenoids have been isolated from this species and the genus *Pouzolzia*.<sup>6-11</sup> Previously, we reported the pharmacological activities of the extracts from *Pouzolzia zeylanica* var. *microphylla*, investigating its anti-inflammatory and analgesic effects,<sup>12</sup> therapeutic effects on mouse subcutaneous abscess<sup>13</sup> and skin ulcers in rats.<sup>14</sup> As part of our continuing study of this plant, two new stilbenes, pouzolignan D (**1**) and K (**2**), and two new norlignans, pouzolignan L (**3**) and M (**4**), along with four known flavonoids (**5-8**) (Figure 1) were obtained. Herein, we reported the isolation, structure elucidation of the four new compounds.


 Figure 1. The structures of compounds **1-8**

## RESULTS AND DISCUSSION

The aerial parts of *P. zeylanica* var. *microphylla* were extracted with petroleum ether and EtOAc, respectively. The resulting EtOAc extract was chromatographed on silica gel, RP-C<sub>18</sub>, sephadex LH-20 and preparative RP-C<sub>18</sub> HPLC to yield compounds **1-8**.

Compound **1** was obtained as brown amorphous powder. Its molecular formula was established as C<sub>26</sub>H<sub>28</sub>O<sub>8</sub> by HR-ESI-TOF-MS ([M-H]<sup>-</sup>, *m/z* 467.1729) and had 13 degrees of unsaturation. The IR spectrum showed the presence of hydroxy group (3360 cm<sup>-1</sup>), aromatic ring (1608, 1520 and 1455 cm<sup>-1</sup>).

The  $^1\text{H}$  NMR spectrum (Table 1) showed two 1,3,4-trisubstituted phenyl rings signals (ABX system) at  $\delta_{\text{H}}$  7.31 (1H, d,  $J = 2.0$  Hz, H-2'''), 7.19 (1H, dd,  $J = 8.5, 2.0$  Hz, H-6'''), 6.98 (1H, d,  $J = 8.5$  Hz, H-5''') and 6.78 (1H, d,  $J = 1.5$  Hz, H-2'), 6.72 (1H, dd,  $J = 8.0, 1.5$  Hz, H-6'), 6.61 (1H, d,  $J = 8.0$  Hz, H-5'), one 1,3,5-trisubstituted phenyl ring signal (AB<sub>2</sub> system) at  $\delta_{\text{H}}$  6.10 (2H, d,  $J = 2.0$  Hz, H-2'', 6''), 6.01 (1H, t,  $J = 2.0$  Hz, H-4'') and three methoxy groups signals at  $\delta_{\text{H}}$  3.87, 3.83, 3.68 (each 3H, s). Since three phenyl rings accounted for 12 out of 13 degrees of unsaturation, the molecule was tetracyclic. NMR and HSQC spectra showed the presence of four methines signals at  $\delta_{\text{H}}$  2.52 (1H, m, H-4) with  $\delta_{\text{C}}$  57.0 (C-4),  $\delta_{\text{H}}$  3.62 (1H, m, H-3) with  $\delta_{\text{C}}$  53.7 (C-3),  $\delta_{\text{H}}$  4.90 (1H, d,  $J = 8.5$  Hz, H-5) with  $\delta_{\text{C}}$  81.8 (C-5),  $\delta_{\text{H}}$  5.20 (1H, d,  $J = 7.5$  Hz, H-2) with  $\delta_{\text{C}}$  83.4 (C-2), which indicated the existence of a tetrahydrofuran ring, and another methylene signal at  $\delta_{\text{H}}$  3.80 (2H, m, H-6) with  $\delta_{\text{C}}$  61.3 (C-6) were recognized.

The NMR data suggested that compound **1** had the same fundamental skeleton as the known compound cestrumoside.<sup>15</sup> The difference between them was **1** had three phenyl rings but cestrumoside had two, and their substituents on the phenyl rings were different. Comparison of the NMR data of **1** with those of cestrumoside showed that C-3 ( $\delta_{\text{C}}$  53.7) was shifted downfield 20.3 ppm, which suggested another phenyl ring attached on C-3 of the tetrahydrofuran ring. And it was confirmed by the HMBC correlations between H-3 and C-1'' and C-2'', 6''. The position of the hydroxy and methoxy groups in compound **1** were established by extensive analysis of the HMBC spectra (Figure 2). The relative *trans* configuration between the methine protons at C-3 and C-4, C-4 and C-5, and *cis* configuration between the methine protons at C-2 and C-3, C-2 and C-5 were established by the 2D NOESY spectral analysis. Thus, the structure of **1**, named pouzolignan D, was elucidated as 5-(3,4-dimethoxyphenyl)-2-(4-hydroxy-3-methoxyphenyl)-3-(3,5-dihydroxyphenyl)-4-(hydroxymethyl)tetrahydrofuran.

Compound **2** was obtained as a brown tabular crystal ( $\text{CHCl}_3$ -MeOH 1:1) and had a molecular formula of  $\text{C}_{30}\text{H}_{28}\text{O}_9$  established by HR-ESI-TOF-MS ( $[\text{M}+\text{Na}]^+$ ,  $m/z$  555.1608,  $[\text{M}-\text{H}]^-$ ,  $m/z$  531.1740), corresponding to 17 degrees of unsaturation. The IR spectrum showed the presence of hydroxy group ( $3351\text{ cm}^{-1}$ ), aromatic ring ( $1605, 1516$  and  $1459\text{ cm}^{-1}$ ). In the  $^1\text{H}$  NMR spectrum (Table 1), two sets of aromatic rings signals at  $\delta_{\text{H}}$  6.85 (2H, d,  $J = 1.5$  Hz, H-2', 2'''), 6.80 (2H, dd,  $J = 8.5, 1.5$  Hz, H-6', 6'''), 6.76 (2H, d,  $J = 8.5$  Hz, H-5', 5''') and 6.11 (4H, d,  $J = 2.0$  Hz, H-2'', 6'', 2''', 6'''), 6.09 (2H, t,  $J = 2.0$  Hz, H-4'', 4''') were recognized, revealing a 1,3,4-trisubstituted phenyl ring (ABX system) and a 1,3,5-trisubstituted phenyl ring (AB<sub>2</sub> system), respectively, as well as one methoxy group signal at  $\delta_{\text{H}}$  3.80 (6H, s, 3', 3'''-OMe). Moreover, the  $^{13}\text{C}$  NMR and DEPT spectra showed ten olefinic carbon signals at

Table 1. NMR spectral data for compounds **1**, **2**  
( $\delta$  in ppm,  $J$  in Hz. 500 MHz for  $^1\text{H}$  NMR and 125 MHz for  $^{13}\text{C}$  NMR)

position	<b>1</b> <sup>a</sup>		position	<b>2</b> <sup>b</sup>	
	$\delta_{\text{C}}$	$\delta_{\text{H}}$		$\delta_{\text{C}}$	$\delta_{\text{H}}$
2	83.4	5.20 (1H, d, 7.5)	2(5)	88.6	5.22 (2H, dd, 6.5, 3.0)
3	53.7	3.62 (1H, m)	3(4)	63.3	3.44 (2H, dd, 6.5, 3.0)
4	57.0	2.52 (1H, m)			
5	81.8	4.90 (1H, d, 8.5)			
6	61.3	3.80 (2H, m)			
1'	131.4		1' (1''')	133.9	
2'	110.7	6.78 (1H, d, 1.5)	2' (2''')	110.4	6.85 (2H, d, 1.5)
3'	146.5		3' (3''')	146.6	
4'	145.0		4' (4''')	148.3	
5'	113.8	6.61 (1H, d, 8.0)	5' (5''')	115.5	6.76 (2H, d, 8.5)
6'	119.3	6.72 (1H, dd, 8.0, 1.5)	6' (6''')	119.4	6.80 (2H, dd, 8.5, 1.5)
1''	144.3		1'' (1''')	141.1	
2'' (6'')	108.1	6.10 (2H, d, 2.0)	2'' (6'', 2''', 6''')	107.3	6.11 (4H, d, 2.0)
3'' (5'')	157.7		3'' (5'', 3''', 5''')	158.9	
4''	100.2	6.01 (1H, t, 2.0)	4'' (4''')	101.8	6.09 (2H, t, 2.0)
1'''	134.5				
2'''	110.6	7.31 (1H, d, 2.0)			
3'''	149.3				
4'''	148.7				
5'''	111.7	6.98 (1H, d, 8.5)			
6'''	118.7	7.19 (1H, dd, 8.5, 2.0)			
3'-OMe	55.1	3.68 (3H, s)	3' (3''')-OMe	55.8	3.80 (6H, s)
3'''-OMe	55.4	3.87 (3H, s)			
4'''-OMe	55.2	3.83 (3H, s)			

<sup>a</sup> in  $\text{CD}_3\text{COCD}_3$ , <sup>b</sup> in  $\text{CD}_3\text{OD}$ .




Figure 2. Selected HMBC correlations (H→C) of compounds 1-4

$\delta_C$  158.9 (C-3'', 5'', 3''', 5'''), 148.3 (C-4', 4'''), 146.6 (C-3', 3'''), 141.1 (C-1'', 1'''), 133.9 (C-1', 1'''), 119.4 (C-6', 6'''), 115.5 (C-5', 5'''), 110.4 (C-2', 2'''), 107.3 (C-2'', 6'', 2''', 6'''), 101.8 (C-4'', 4'''), two tertiary methyl carbon signals at  $\delta_C$  88.6 (C-2, 5), 63.3 (C-3, 4) and one methoxy group signal at  $\delta_C$  55.8 (3', 3'''-OMe).

Furthermore, comparing the molecular formula  $C_{30}H_{28}O_9$  and 17 degrees of unsaturation of compound **2** with its fewer  $^1H$  NMR and  $^{13}C$  NMR signals, it indicated that this molecule had symmetrical elements and overlapping carbon signals with four phenyl rings and the integration of hydrogen in the  $^1H$  NMR spectrum should be doubled. Thus, compound **2** had four phenyl rings which accounted for 16 units of the 17 degrees of unsaturation and the molecule was pentacyclic. Moreover, the  $^1H$  NMR,  $^{13}C$  NMR and HSQC spectra revealed four methines signals at  $\delta_H$  3.44 (2H, dd,  $J = 6.5, 3.0$  Hz, H-3, 4) with  $\delta_C$  63.3 (C-3, 4) and  $\delta_H$  5.22 (2H, dd,  $J = 6.5, 3.0$  Hz, H-2, 5) with  $\delta_C$  88.6 (C-2, 5), which suggested the presence of a tetrahydrofuran ring with symmetry substituents. From the above-mentioned analysis and HMBC correlations (Figure 2), it suggested that the four phenyl groups were linked to the four carbons of

tetrahydrofuran ring, respectively. It showed **2** was similar to compound **1** and had a symmetrical structure. Confirming evidence was obtained from the HMBC correlations of H-2, 5 with C-3, 4, C-2', 2''', C-6', 6''' and H-3, 4 with C-1', 1''', C-1'', 1''', C-2'', 6'', 2''', 6'''. The location of the methoxy group at C-3', 3''' were proved by HMBC correlation between methoxy protons ( $\delta_{\text{H}}$  3.80) and C-3', 3''' ( $\delta_{\text{C}}$  146.6) and NOESY interactions of methoxy protons with H-2', 2'''. The relative *trans* configuration between the methine protons at C-2, 5 and C-3, 4 were established by the weak interactions between H-2, 5 and H-3, 4 in the 1D and 2D NOESY spectra. Moreover, its basic skeleton is similar to the known (2*S*,3*R*,4*R*,5*S*)-2,3,4,5-tetrakis(4-methoxyphenyl)tetrahydrofuran<sup>16</sup> and tricuspidatol-A.<sup>17</sup> The <sup>1</sup>H NMR data of former compound showed the tetrahydrofuran signals at  $\delta_{\text{H}}$  5.26 (2H, dd,  $J = 6.3, 2.7$  Hz) and 3.52 (2H, dd,  $J = 6.3, 2.7$  Hz), while the data of tricuspidatol-A at  $\delta_{\text{H}}$  5.25 (2H, dd,  $J = 5.0, 1.5$  Hz) and 3.50 (2H, dd,  $J = 5.0, 1.5$  Hz), which both resemble the data of compound **2**. Thus, on the basis of 2D NOESY of **2**, we confirmed the relative stereochemistry structures of **2** in Figure 1. Consequently, the structure of **2**, named pouzolignan K, was characterized as 2,5-bis(4-hydroxy-3-methoxyphenyl)-3,4-bis(3,5-dihydroxyphenyl)tetrahydrofuran.

Compound **3** was obtained as white powder, the molecular formula of C<sub>27</sub>H<sub>30</sub>O<sub>9</sub> was determined from the HR-ESI-TOF-MS ( $[\text{M}+\text{Na}]^+$ ,  $m/z$  521.1786), suggesting 13 degrees of unsaturation. The UV spectrum showed absorption maxima at 275 and 281 nm in methanol, and the IR spectrum showed absorption bands at 3362, 1720, 1601, 1512 and 1462 cm<sup>-1</sup>, indicating the presence of hydroxy group, carbonyl group, and aromatic ring. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectrum of **3** (Table 2) along with analysis of the DEPT spectra displayed 27 carbon signals and 30 proton signals. In the <sup>1</sup>H-NMR spectrum of **3** (Table 2), two 1, 3, 4-trisubstituted protons (ABX system) at  $\delta_{\text{H}}$  6.94 (1H, d,  $J = 2.0$  Hz, H-2'), 6.90 (1H, dd,  $J = 2.0, 8.0$  Hz, H-6'), 6.82 (1H, d,  $J = 8.0$  Hz, H-5'), and 6.76 (1H, d,  $J = 2.0$  Hz, H-2''), 6.65 (1H, dd,  $J = 8.0, 2.0$  Hz, H-6''), 6.63 (1H, d,  $J = 8.0$  Hz, H-5''), one 1, 3, 5-trisubstituted phenyl protons (AB<sub>2</sub> system) at  $\delta_{\text{H}}$  6.17 (2H, d,  $J = 2.0$  Hz, H-2''', 6'''), 6.19 (1H, t,  $J = 2.0$  Hz, H-4'''), three methine protons at  $\delta_{\text{H}}$  2.84-2.88 (1H, m, H-2), 3.13-3.17 (1H, m, H-3), 3.37 (1H, d,  $J = 12.0$  Hz, H-5), two oxymethylene protons at  $\delta_{\text{H}}$  3.31-3.37 (2H, m, H-1), 4.51-4.59 (2H, m, H-4), two methoxyl protons at  $\delta_{\text{H}}$  3.90, 3.78 (each 3H, s), as well as an acetyl methyl protons at  $\delta_{\text{H}}$  1.94 (3H, s) were recognized. DEPT experiment revealed that **3** had ten quaternary carbons, twelve tertiary carbons, two methylenes and three methyl groups (Table 2). In the HMBC spectrum, correlations of H-5 ( $\delta_{\text{H}}$  3.37) with C-1' ( $\delta_{\text{C}}$  137.9), C-6' ( $\delta_{\text{C}}$  121.9), C-1'' ( $\delta_{\text{C}}$  137.3), and C-6'' ( $\delta_{\text{C}}$  121.1), proved that the two 1, 3, 4-trisubstituted phenyl rings were both linked to C-5.

Table 2. NMR spectral data for compounds **3**, **4** and pouzolignan F  
(in CD<sub>3</sub>OD,  $\delta$  in ppm,  $J$  in Hz. 500 MHz for <sup>1</sup>H NMR and 125 MHz for <sup>13</sup>C NMR)

position	<b>3</b>		<b>4</b>		pouzolignan F <sup>a</sup>	
	$\delta_C$	$\delta_H$	$\delta_C$	$\delta_H$	$\delta_C$	$\delta_H$
1	63.2	3.31-3.37 (2H, m)	63.2	3.28-3.35 (2H, m)	65.6	3.72 (1H, dd, 11.5, 4.5) 4.05 (1H, dd, 11.5, 4.0)
2	46.7	2.84-2.88 (1H, m)	46.7	2.82-2.89 (1H, m)	42.3	3.12-3.14 (1H, m)
3	46.5	3.13-3.17 (1H, m)	46.5	3.16-3.19 (1H, m)	48.9	3.01-3.04 (1H, m)
4	69.7	4.51-4.59 (2H, m)	69.7	4.53-4.72 (2H, m)	65.6	3.96-3.98 (1H, m) 3.84 (1H, d, 7.5)
5	53.2	3.37 (1H, d, 12.0)	53.7	3.36 (1H, d, 12.0)	53.5	3.65 (1H, d, 12.0)
1'	137.9		137.1		137.1	
2'	113.4	6.94 (1H, d, 2.0)	113.5	6.96 (1H, d, 2.0)	113.2	7.05 (1H, d, 2.0)
3'	149.3		149.3		149.3	
4'	146.0		146.1		146.0	
5'	116.6	6.82 (1H, d, 8.0)	116.6	6.83 (1H, d, 8.0)	116.2	6.82 (1H, d, 8.0)
6'	121.9	6.90 (1H, dd, 8.0, 2.0)	121.9	6.92 (1H, dd, 8.0, 2.0)	122.1	6.95 (1H, dd, 8.0, 2.0)
1''	137.3		137.2		136.7	
2''	112.4	6.76 (1H, d, 2.0)	105.9	6.48 (1H, s)	112.7	6.84 (1H, d, 2.0)
3''	149.0		149.4		148.9	
4''	145.8		134.9		145.8	
5''	116.3	6.63 (1H, d, 8.0)	149.4		116.2	6.65 (1H, d, 8.0)
6''	121.1	6.65 (1H, dd, 8.0, 2.0)	105.9	6.48 (1H, s)	121.5	6.70 (1H, dd, 8.0, 2.0)
1'''	142.4		142.4		142.9	
2''', 6'''	109.5	6.17 (2H, d, 2.0)	109.5	6.18 (2H, d, 2.0)	109.1	6.10 (2H, d, 2.0)
3''', 5'''	159.3		159.3		159.3	
4'''	102.3	6.19 (1H, t, 2.0)	102.3	6.19 (1H, t, 2.0)	102.2	6.19 (1H, t, 2.0)

3'-OMe	56.7	3.90 (3H, s)	56.7	3.90 (3H, s)	56.6	3.92 (3H, s)
3''-OMe	56.5	3.78 (3H, s)	56.9	3.79 (3H, s)	56.5	3.80 (3H, s)
5''-OMe			56.9	3.79 (3H, s)		
Ac	21.1	1.94 (3H, s)	21.1	1.94 (3H, s)	20.6	1.87 (3H, s)
	173.2		173.2		172.8	

<sup>a</sup> data from 11.

Furthermore, H-3 ( $\delta_{\text{H}}$  3.13-3.17) with C-2''', 6''' ( $\delta_{\text{C}}$  109.5) indicated that the 1, 3, 5-trisubstituted phenyl ring was attached to C-3 as well (Figure 2).

The NMR data suggested that compound **3** had the uniform norlignan skeleton as pouzolignan F<sup>11</sup> which was reported in our earlier phytochemical investigations. Comparing the NMR data of **3** with those of pouzolignan F, C-4 ( $\delta_{\text{C}}$  69.7) was shifted downfield 4.1 ppm and C-3 ( $\delta_{\text{C}}$  46.5) was shifted upfield 2.4 ppm, as well as correlations between H-4 with C-1''', C-3, CH<sub>3</sub>CO in HMBC, thus, the acetoxy group was attached to C-4. The position of the hydroxy and methoxy groups in compound **3** were established by extensive analysis of the HMBC spectra (Figure 2). Based on the above results, the structure of **3**, named pouzolignan L, was established as 1-hydroxy-3-(3,5-dihydroxyphenyl)-2-[bis(4-hydroxy-3-methoxyphenyl)methyl]butyl acetate.

Compound **4** was obtained as white powder, the molecular formula of C<sub>28</sub>H<sub>32</sub>O<sub>10</sub> was assigned from the HR-ESI-TOF-MS ([M+Na]<sup>+</sup>, *m/z* 551.1889), suggesting 13 degrees of unsaturation. The <sup>1</sup>H and <sup>13</sup>C NMR spectral data of **4** (Table 2) were similar to those of **3**, except for the presence of an additional methoxy group at  $\delta_{\text{H}}$  3.79 (3H, s) and  $\delta_{\text{C}}$  56.9, and the 1, 3, 4, 5-tetrasubstituted phenyl signals at  $\delta_{\text{H}}$  6.48 (2H, s, H-2'', 6'') with  $\delta_{\text{C}}$  105.9 (C-2'', 6''). The location of the methoxy group at C-5'' was confirmed by the HMBC correlation (Figure 2). Hence, the structure of **4**, named pouzolignan M, was identified as 1-hydroxy-3-(3,5-dihydroxyphenyl)-2-[4-hydroxy-3-methoxyphenyl-(4-hydroxy-3,5-dimethoxyphenyl)]butyl acetate.

The known compounds were identified as rhamnocitrin (**5**), rhamnetin (**6**),<sup>18</sup> isorhamnetin (**7**)<sup>19</sup> and quercetin (**8**),<sup>20</sup> by comparing the spectroscopic data with those reported in the literature values.

## EXPERIMENTAL

**General** UV spectra were obtained using a Shimadzu UV-2450 spectrophotometer. IR spectra were recorded on a Nicolet 6700 FT-IR spectrometer. NMR spectra were run on a Bruker AVANCE III 500



spectrometer with TMS as internal standard, and the chemical shifts ( $\delta$ ) were expressed in ppm. HR-ESI-TOF-MS was performed on an API QSTAR time-of-flight spectrometer. TLC was performed on precoated silica gel GF254 plates from Yantai Jiangyou Company. Silica gel 100-200, 200-300 and 300-400 mesh from Qingdao Haiyang Chemical Company, YWG-C<sub>18</sub> (50-70  $\mu$ m) from Tianjin Boruijianhe Chromatography Technology Company and Sephadex LH-20 from Amersham Biosciences were used for column chromatography. Preparative RP-C<sub>18</sub> HPLC was performed by a Shimadzu LC-6AD series instrument with Shim-Park RP-C<sub>18</sub> column (20 $\times$ 200 mm i.d.).

**Plant material** The aerial parts of *P. zeylanica* var. *microphylla* were collected in Guangzhou, Guangdong province of China on January, 2012 and identified by Professor Ji-Zhu Liu, Guangdong Pharmaceutical University. A voucher specimen (No. 20120113) has been deposited in the Lab of Traditional Chinese Medicine Chemistry, Guangdong Pharmaceutical University.

**Extraction and Isolation** The air-dried and powdered aerial parts of *P. zeylanica* var. *microphylla* (5 kg) were extracted with petroleum ether (150 L) under reflux for two times (1 h per time). After the solvent on the plants was volatilized completely, the plants were extracted with EtOAc (150 L) under reflux for three times (1.5 h per time), which was evaporated under reduced pressure to yield a residue (80 g). The EtOAc extract was subjected to silica gel (100-200 mesh) column chromatography, eluted with petroleum ether-EtOAc (50:1 $\rightarrow$ 1:1), EtOAc, CH<sub>2</sub>Cl<sub>2</sub>-MeOH (1:1), MeOH to yield six fractions, Fr.A-F. Fr.D (13.4 g) was resubjected by silica gel (200-300 mesh) column chromatography, eluted with CHCl<sub>3</sub>-MeOH (50:1 $\rightarrow$ 5:1) to yield Fr.D1-D5. Fr.D1 was separated by Sephadex LH-20, eluted with CHCl<sub>3</sub>-MeOH (1:1) and purified by RP-C<sub>18</sub> column (50-70  $\mu$ m), using 70% MeOH as the eluent to afford **2** (7.5 mg). Fr.D2 was subjected to sephadex LH-20, eluted with CHCl<sub>3</sub>-MeOH (1:1) to yield four fractions, and the second fraction (0.3 g) was purified by RP-C<sub>18</sub> column (50-70  $\mu$ m), eluted with 70% MeOH to afford **1** (17 mg). Fr.E (4 g) was resubjected to silica gel (200-300 mesh) column chromatography, eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (25:1 $\rightarrow$ 8:1) to yield Fr.E1-E4. Fr.E2 was separated repeatedly by silica gel (300-400 mesh) column chromatography, eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (17:1) and finally by preparative RP-C<sub>18</sub> HPLC, eluted with MeOH-H<sub>2</sub>O-HCO<sub>2</sub>H (23:1:0.5) to afford **3** (14 mg). Fr.E3 was further fractionated repeatedly by silica gel (300-400 mesh) column chromatography, eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (14:1), then was separated by Sephadex LH-20, eluted with CHCl<sub>3</sub>-MeOH (3:2) to afford **4** (14 mg). Fr.F (14 g) was

submitted to silica gel (200-300 mesh) column chromatography, eluted with  $\text{CHCl}_3$ -MeOH (20:1→1:1) to afford Fr.F1-F6. Fr.F2 (0.5 g), Fr.F4 (1.0 g) and Fr.F5 (0.3 g) were subjected to Sephadex LH-20, eluted with MeOH to yield compounds **5** (15 mg), **6** (15 mg), **7** (18 mg) and **8** (25 mg), respectively.

**Pouzolignan D (1)** : Brown amorphous powder;  $[\alpha]_D^{20} +34.0$  (*c* 0.1, MeOH); IR (KBr)  $\nu_{\text{max}}$  3360, 2940, 2840, 1608, 1520, 1455, 1347, 1270, 1150, 820  $\text{cm}^{-1}$ ; UV (MeOH)  $\lambda_{\text{max}}$  nm (log  $\epsilon$ ) 274 (4.02); HR-ESI-TOF-MS  $m/z$  467.1729  $[\text{M-H}]^-$  (calcd 467.1733 for  $\text{C}_{26}\text{H}_{27}\text{O}_8^-$ ),  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (see Table 1).

**Pouzolignan K (2)**: Brown tabular crystals ( $\text{CHCl}_3$ -MeOH 1:1);  $[\alpha]_D^{20} +71.4$  (*c* 0.1, MeOH); IR (KBr)  $\nu_{\text{max}}$  3351, 1605, 1516, 1459, 1435, 1273, 1238, 1156, 1124, 1031, 1001 and 921  $\text{cm}^{-1}$ ; UV (MeOH)  $\lambda_{\text{max}}$  nm (log  $\epsilon$ ) 280 (4.13); HR-ESI-TOF-MS  $m/z$  555.1608  $[\text{M}+\text{Na}]^+$ , 531.1740  $[\text{M-H}]^-$  (calcd 555.1611 for  $\text{C}_{30}\text{H}_{28}\text{NaO}_9^+$ , 531.1743 for  $\text{C}_{30}\text{H}_{27}\text{O}_9^-$ ),  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (see Table 1).

**Pouzolignan L (3)**: white powder;  $[\alpha]_D^{20} +29.7$  (*c* 0.1, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  nm (log  $\epsilon$ ) 275 (3.25); IR (KBr)  $\nu_{\text{max}}$  3362, 2942, 1720, 1601, 1512, 1462, 1365, 1128 and 849  $\text{cm}^{-1}$ , HR-ESI-TOF-MS  $m/z$  521.1786  $[\text{M}+\text{Na}]^+$  (calcd 521.1788 for  $\text{C}_{27}\text{H}_{30}\text{NaO}_9^+$ ),  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (see Table 2).

**Pouzolignan M (4)**: white powder;  $[\alpha]_D^{20} +36.1$  (*c* 0.1, MeOH), UV (MeOH)  $\lambda_{\text{max}}$  nm (log  $\epsilon$ ) 275(3.34); IR (KBr)  $\nu_{\text{max}}$  3362, 2941, 1721, 1602, 1514, 1462, 1366, 1126 and 849  $\text{cm}^{-1}$ ; HR-ESI-TOF-MS  $m/z$  551.1889  $[\text{M}+\text{Na}]^+$  (calcd 551.1893 for  $\text{C}_{28}\text{H}_{32}\text{NaO}_{10}^+$ )  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (see Table 2).

## ACKNOWLEDGEMENTS

This work was financially supported by the National Natural Science Foundation (NNSF) of China (NO. 81073045) and the Chinese Medicine Administration Bureau of Guangdong, China (NO. 20141162).

## REFERENCES

1. Flora of China Editorial Committee, 'Flora of China Illustrations', Vol. 5, ed. by Science Press & Missouri Botanical Garden Press, Inc., Beijing, 2004, pp. 177-178.
2. D. Saha, S. Paul, and S. Chowdhury, *Int. J. Pharm. Inn.*, 2012, **2**, 1.
3. B. D. Xiao, 'Lingnan Cai Yao Lu', ed. by Guangdong Science and Technology Press, Inc., Guangzhou, 2009, pp. 137-139.
4. D. R. Dangol and S. B. Gurung, *Pharm. Biol.*, 1991, **29**, 203.
5. P. Y. Li, L. N. Huo, W. Su, R. M. Lu, C. C. Deng, L. Q. Liu, Y. K. Deng, N. N. Guo, C. S. Lu, and

- C. L. He, *J. Serb. Chem. Soc.*, 2011, **76**, 709.
6. L. T. Thuy, L.V. Kinh, and T. L. Quan, *The 13th Animal Science Congress of the Asian*, 2008.
  7. M. Mohammed, A. R. Maxwell, R. Ramsewak, and W. F. Reynolds, *Phytochem. Lett.*, 2010, **3**, 29.
  8. M. Fu, Y.Y. Niu, J. Yu, and Q.T. Kong, *J. Chin. Med. Mat.*, 2012, **35**, 1778.
  9. Z. Luo, C. Q. Zhong, X. Y. Liu, Z. B. Yi, and L. B. Guo, *J. Guangdong Pharm. Univ.*, 2014, **30**, 430.
  10. X. Y. Liu, Y. F. Xie, H. Zhang, T. Z. Liu, C. Wen, and L. B. Guo, *Chin. J. Exp. Tradit. Med. Form.*, 2014, **20**, 43.
  11. Z. H. Chen, H. Zhang, S. H. Tao, Z. Luo, C. Q. Zhong, and L. B. Guo, *J. Asian Nat. Prod. Res.*, 2015, 1.
  12. X. Y. Liu, Q. T. Du, K. Y. Li, Q. Deng, and L. B. Guo, *Drugs Clinic*, 2012, **27**, 356.
  13. K. Y. Li, Y. F. Xie, Y. F. Chen, T. Z. Liu, and L. B. Guo, *J. Guangdong Pharm. Univ.*, 2012, **28**, 540.
  14. Y. F. Chen, K. Y. Li, Q. Deng, X. Y. Liu, Z. B. Shen, and L. B. Guo, *Tradit. Chin. Drug. Res. Clin. Pharmacol.*, 2013, **24**, 247.
  15. K. M. Mohamed, M. A. Fouad, K. Matsunami, M. S. Kamel, and H. Otsuka, *ARKIVOC*, 2007, **xiii**, 63.
  16. F. J. Hong, Y. Y. Low, K. W. Chong, N. F. Thomas, and T. S. Kam, *J. Org. Chem.*, 2014, **79**, 4528.
  17. A. P. Lins, J. D. Felicio, M. M. Braggio, and L. C. Roque, *Phytochemistry.*, 1991, **30**, 3144.
  18. W. T. Li, P. Ying, and J. Y. Zhang, *J. Nat. Prod.*, 2009, **72**, 1057.
  19. Y. Zhang and Y. M. Zhao, *China J. Chin. Mater. Med.*, 2005, **30**, 679.
  20. X. F. Xu, H. J. Li, and P. Li, *Chin. J. Nat. Med.*, 2006, **4**, 45.